160 Results for "

auto-phosphorylation

" in MedChemExpress (MCE) Product Catalog:
Products (160)

160 Results for "auto-phosphorylation" in MCE Product Catalog:

307
307 Publications Verification
Cat. No.: HY-10201
CAS No.: 284461-73-0
Purity:  99.92%
Synonyms: Bay 43-9006
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
307
307 Publications Verification
Cat. No.: HY-10201A
CAS No.: 475207-59-1
Purity:  99.75%
Synonyms: Bay 43-9006 tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
217
217 Cited Publications
Cat. No.: HY-50895
CAS No.: 184475-35-2
Synonyms: ZD1839
Target:  

EGFR Autophagy Apoptosis

Research Areas:  

Cancer

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
loading...
    loading...
217
217 Cited Publications
Cat. No.: HY-50895A
CAS No.: 184475-55-6
Synonyms: ZD-1839 hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity .
loading...
    loading...
108
108 Cited Publications
Cat. No.: HY-10255A
CAS No.: 557795-19-4
Purity:  99.04%
Synonyms: SU 11248
Research Areas:  

Cancer

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
108
108 Cited Publications
Cat. No.: HY-10255
CAS No.: 341031-54-7
Purity:  99.86%
Synonyms: SU 11248 Malate
Sunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
108
108 Cited Publications
Cat. No.: HY-10255C
CAS No.: 1818285-48-1
Synonyms: SU 11248 glucuronate
Research Areas:  

Cancer

Sunitinib (SU 11248) glucuronate is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib glucuronate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
loading...
    loading...
48
48 Cited Publications
Cat. No.: HY-13001
CAS No.: 950769-58-1
Purity:  99.08%
Synonyms: AC220
Target:  

FLT3 Apoptosis PDGFR c-Kit

Research Areas:  

Cancer

Quizartinib (AC220) is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .
loading...
    loading...
48
48 Cited Publications
Cat. No.: HY-14217
CAS No.: 1132827-21-4
Purity:  99.81%
Synonyms: AC220 dihydrochloride
Target:  

FLT3 Apoptosis PDGFR c-Kit

Research Areas:  

Cancer

Quizartinib (AC220) dihydrochloride is an orally active, potent and selective FLT3 inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-12444
CAS No.: 4506-66-5
Purity:  ≥98.0%
Synonyms: FAK Inhibitor 14
Target:  

FAK

Research Areas:  

Cancer

Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-13012
CAS No.: 446859-33-2
Purity:  99.92%
Synonyms: E-616452; SJN 2511
Research Areas:  

Metabolic Disease

RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-103248
CAS No.: 606-58-6
Purity:  99.78%
Synonyms: Vengicide
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-17537
CAS No.: 1216665-49-4
Target:  

IRE1

Research Areas:  

Cancer

APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-10367
CAS No.: 267243-28-7
Purity:  99.74%
Synonyms: CI-1033; PD-183805
Target:  

EGFR Orthopoxvirus

Research Areas:  

Infection Cancer

Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-13258A
CAS No.: 940310-85-0
Purity:  99.71%
Synonyms: BHG712
Target:  

Ephrin Receptor

Research Areas:  

Cancer

NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-10367A
CAS No.: 289499-45-2
Purity:  99.68%
Synonyms: CI-1033 dihydrochloride; PD-183805 dihydrochloride
Target:  

EGFR Orthopoxvirus

Research Areas:  

Infection Cancer

Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-122727
CAS No.: 1326852-06-5
Purity:  ≥98.0%
Target:  

DNA-PK Apoptosis

Research Areas:  

Cancer

STL127705 (Compound L) is a potent Ku 70/80 heterodimer protein inhibitor with an IC50 of 3.5 μM. STL127705 interferes the binding of Ku70/80 to DNA and by inhibits the activation of the DNA-PKCS kinase. STL127705 shows antiproliferative and anticancer activity. STL127705 induces apoptosis .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-116624
CAS No.: 163655-37-6
Purity:  99.76%
Target:  

VEGFR Apoptosis

Research Areas:  

Cancer

MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15002
CAS No.: 630124-46-8
Purity:  98.90%
Synonyms: NVP-AST 487
Target:  

RET FLT3 VEGFR c-Kit Bcr-Abl

Research Areas:  

Cancer

AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101957
CAS No.: 71897-07-9
Purity:  99.86%
Target:  

PDGFR

Research Areas:  

Cardiovascular Disease

AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .
loading...
    loading...